Merck & Co., Inc. (MRK.PA)
Paris - Paris Delayed price. Currency in EUR
Add to watchlist
As of 05:35PM CEST. Market open.
| Previous close | 101.40 |
| Open | 100.20 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 100.20 - 101.60 |
| 52-week range | 100.20 - 110.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 260.608B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 21.04 |
| EPS (TTM) | N/A |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Merck raises 2024 guidance on cancer drug demand
Shares of Merck & Company (MRK) are trading higher early Thursday after the pharmaceutical giant posted robust sales results in the first quarter, leading the pharmaceutical giant to raise its 2024 outlook. The company's performance was driven by strong demand for its cancer drug Keytruda. Yahoo Finance's Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance. This post was written by Angel Smith
Simply Wall St.We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Business WireMerck Announces First-Quarter 2024 Financial Results
RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results
© 2024 Yahoo. All rights reserved.